Cancer clinical trials in the region Pays de la Loire

443 currently recruiting clinical trials
Region Pays de la Loire
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07397338 #2025-524623-50-00
Cohorte Tumeur solide /CRC (bras C pour l'expansion de dose de la partie 2)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Required number of previous lines of therapy
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Lung cancer #NCT07397338 #2025-524623-50-00
Cohorte NSCLC (bras A et B expansion de dose de la partie 2)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05706129 #2023-504254-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2 Prostate cancer #NCT04104776 #2023-508002-20-00
Cohorte M6
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04104776 #2023-508002-20-00
Cohorte M1
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Endometrial cancer #NCT04104776 #2023-508002-20-00
Cohorte M3
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Lung cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04104776 #2023-508002-20-00
Cohorte M5
Required histologic types
Mesothelium Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Lymphoma #NCT04104776 #2023-508002-20-00
Cohorte M4
Required histologic types
B cell lymphoma T cell lymphoma
Required histologic sub types
Large B cell lymphoma Peripheral T cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
6 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Endometrial cancer #NCT04104776 #2023-508002-20-00
Cohorte M7
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
ARID1A
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04104776 #2023-508002-20-00
Cohorte M2
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis Pharmaceuticals